(Q38390840)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

review article

1 reference

title

Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

0 references

1 reference

metastatic colon cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Glen A Doherty

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Elizabeth J. Ryan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Louise Elliott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Fennelly

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kieran Sheahan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Biomarkers in Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

363-375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808440%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

3 March 2020

cites work

1 reference

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

21 January 2018

1 reference

Targeted therapies in colorectal cancer-an integrative view by PPPM

21 January 2018

1 reference

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development

21 January 2018

1 reference

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

RAS oncogenes: weaving a tumorigenic web

21 January 2018

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

21 January 2018

1 reference

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

21 January 2018

1 reference

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

21 January 2018

1 reference

BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications

21 January 2018

1 reference

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis

21 January 2018

1 reference

US National Cancer Institute's new Ras project targets an old foe.

21 January 2018

1 reference

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

21 January 2018

1 reference

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

21 January 2018

1 reference

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

21 January 2018

1 reference

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

21 January 2018

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients

21 January 2018

1 reference

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

21 January 2018

1 reference

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis

21 January 2018

1 reference

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

21 January 2018

1 reference

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

21 January 2018

1 reference

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

21 January 2018

1 reference

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

21 January 2018

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

21 January 2018

1 reference

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

21 January 2018

1 reference

HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome

21 January 2018

1 reference

Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer

21 January 2018

1 reference

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

21 January 2018

1 reference

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

21 January 2018

1 reference

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.

21 January 2018

1 reference

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

21 January 2018

1 reference

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

21 January 2018

1 reference

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

21 January 2018

1 reference

The ADAMs: signalling scissors in the tumour microenvironment

21 January 2018

1 reference

TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer

21 January 2018

1 reference

Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17

21 January 2018

1 reference

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

21 January 2018

1 reference

ADAM-17: a novel therapeutic target for triple negative breast cancer

21 January 2018

1 reference

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo

21 January 2018

1 reference

ADAM17: a molecular switch to control inflammation and tissue regeneration

21 January 2018

1 reference

IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity

21 January 2018

1 reference

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

21 January 2018

1 reference

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

21 January 2018

1 reference

Targeting CD137 enhances the efficacy of cetuximab.

21 January 2018

1 reference

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells.

21 January 2018

1 reference

The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials

21 January 2018

1 reference

Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.

21 January 2018

1 reference

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

MicroRNAs, ultraconserved genes and colorectal cancers

21 January 2018

1 reference

MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

21 January 2018

1 reference

Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression

21 January 2018

1 reference

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer

21 January 2018

1 reference

RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets

21 January 2018

1 reference

An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration

21 January 2018

1 reference

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan

21 January 2018

1 reference

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

21 January 2018

1 reference

Non-viral vectors for gene-based therapy

21 January 2018

1 reference

Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients.

21 January 2018

1 reference

Genomic era diagnosis and management of hereditary and sporadic colon cancer.

21 January 2018

1 reference